Dishman Pharmaceuticals & Chemicals Ltd, a contract research & manufacturing services (CRAM) major, received the US Food and Drug Administration (USFDA) nod for producing Active Pharmaceutical Ingredients (API) at its Naroda facility here.
The USFDA team has completed the inspection of Dishman's facility situated at Naroda, in Ahmedabad and has approved the facility for API production for the US market, the company said here today.
The Naroda-based facility of Dishman is an Export Oriented Unit (EOU).
The company has recently announced Rs 125 crore capex plans by March end, and also plans to invest another Rs 125-150 crore next year for opening two new API units.
Dishman reported subdued third quarter numbers with net sales declining by 21.2 per cent to Rs 222.3 crore on account of the fall in sales of its Swiss subsidiary. The net sales of Carbogen Amcis fell by 27.5 per cent year-on-year (yoy) to Rs 81.8 crore.
It has now begun a restructuring of its subsidiary to boost bottomlines next year.